Project description

MDS-CAN is a national MDS observational Canadian registry that enrols patients with MDS, CMML and oligoblastic AML within 1 year of diagnosis.

The primary objective is to evaluate the impact of patient related factors on survival and patient reported outcomes in a prospective fashion.

Secondary objectives include:

1. To evaluate 'real-world' clinical outcomes of MDS specific therapies, transfusions and iron overload
2. To refine existing prognostic scores with patient related factors to inform patient care
3. To provide resources for cost-effectiveness analysis